Profit looks boosted by one-off gains.Reported profit is 1.1× operating cash profit (EBITDA), lifted by income outside the core business.Reported profit is 1.1× operating cash profit, lifted by income outside the core business.
Hinge Health's reported profit is 1.1× its operating cash profit (EBITDA), which is unusual: normally it's the other way round. Income outside the core business, such as interest on a large cash pile, gains on investments or asset sales, or tax items, has lifted net income, so its earnings-based valuation may look cheaper than the business alone justifies.Hinge Health's reported profit is 1.1× its operating cash profit, which is unusual: normally it's the other way round. Income outside the core business, such as interest on a large cash pile, gains on investments or asset sales, or tax items, has lifted net income, so its earnings-based valuation may look cheaper than the business alone justifies.
Earnings turned from a loss to a profit. Profit per share this year after a loss last year.
Hinge Health made a profit per share in its latest year after a loss the year before.
Cash flow well above reported profit. Free cash flow is 2.7× reported profit.
Free cash flow is 2.7× reported profit. Large non-cash charges, such as depreciation, amortization or stock-based pay, reduce reported profit without using cash.
Fast revenue growth. Revenue grew 50% in the 12 months to June 2026 vs the 12 months before, faster than 90% of peers.
Revenue grew 50% in the 12 months to June 2026 vs the 12 months before, faster than 90% of its peers.
StockQuotient Score
70/ 100▼ 1 since Oct 27 closeOct 5 71 → Nov 4 70 (-1)
Since last quarter: No major changeValuation also moves with the share price every day.
Why it changed since the Oct 27, 2026 close: Score 40 → 39
Peer companies moved-1
Each step re-scores the company against its peers as they were on Oct 28, 2026; the parts add up to the change. Price effects on EBITDA yield are approximate.
Yahoo Finance fallback · no standard SEC debt tagReported value33% base weight · Z-score 1.00Sector median: 0.2215 · MAD: 0.2039
Valuation, growth and profitability scores: higher is better. Risk: 0 is lower, 2 is higher. Risk is a relative proxy, not a bankruptcy probability. Scores depend on available sector peers.
Questions investors ask about Hinge Health
Is Hinge Health getting weaker?
Its latest SEC filing (Aug 6, 2026) got stronger: turned profitable over the last 12 months; operating margin rose 94.6 points to 13.0%. Its overall score is 70/100, down 1 since Oct 28, 2026.
How is Hinge Health valued vs its peers?
Priced higher than most peers relative to what it earns. Valuation scores 39/100 against 1,393 healthcare peers.EBITDA yield 1.1% vs a peer median of 4.0% (weaker than 64% of peers).EBITDA yield 1.1% vs peers 4.0% (weaker than 64% of peers).
Is Hinge Health growing?
Yes, faster than most of its peers. Growth scores 93/100 against 1,393 healthcare peers.Revenue growth 49.8% vs a peer median of 6.1% (stronger than 90% of peers).Revenue growth 49.8% vs peers 6.1% (stronger than 90% of peers).
How profitable is Hinge Health?
More profitable than most of its peers. Profitability scores 95/100 against 1,393 healthcare peers.Return on invested capital 127.4% vs a peer median of 4.7% (stronger than 95% of peers).Return on invested capital 127.4% vs peers 4.7% (stronger than 95% of peers).
How risky is Hinge Health?
Moderate risk relative to 1,393 healthcare peers, judged on debt, liquidity and share-price swings.Debt / equity 0.02× vs a peer median of 0.22× (stronger than 86% of peers).Debt / equity 0.02× vs peers 0.22× (stronger than 86% of peers).Current ratio 1.34× vs a peer median of 2.59× (weaker than 79% of peers).Current ratio 1.34× vs peers 2.59× (weaker than 79% of peers). A relative measure, not a bankruptcy probability.
Latest filing: what changed
Quarter ended Jun 30, 2026 · filed Aug 6, 2026 · compared with the quarter ended Mar 31, 2026
Got stronger
Turned profitable over the last 12 months
Operating margin rose 94.6 points to 13.0%
Previous quarter
Latest quarter
Change
Revenue (12 months)
646.3M USD
720.1M USD
+11.4%
Net income (12 months)
−510.3M USD
109.1M USD
turned positive
Operating margin
-81.6%
13.0%
+94.6 pts
Free cash flow (12 months)
208.9M USD
290.1M USD
+38.9%
Cash
186.7M USD
286.2M USD
+53.3%
From the company’s own SEC filings, as filed. Twelve-month figures roll forward one quarter at a time.
Industry valuation context
Sector: Healthcare · 301 companies
Valuations in Healthcare are within their usual range since 2016.
52% of months since 2016 were valued lower than now.
19% of companies are in the most expensive fifth of their own price-to-sales history.
Over 24 months, company values +8% and earnings +24% (medians): earnings grew faster than prices.
Median price-to-sales is +63% vs the whole market, against a usual +119%.
2016Shaded: most expensive fifth of its range2026
Shown for Healthcare: too few Health Information Services companies have a long enough history of their own.
Earnings-based measures are left out for now because many companies in Healthcare are losing money.
Describes valuations since 2016; it does not predict prices. US companies worth $1B+, from SEC filings and month-end prices, as of Aug 2026. Today's companies and industry labels are used throughout. Measured on sales and free cash flow yields. How this works
Financials
Fiscal years from SEC annual filings · change vs the prior year
Key ratios
FY 2023
FY 2024
FY 2025
Change
Gross margin
66.3%
76.8%
79.6%
▲ 2.8 pts
Operating margin
-44.6%
-8.2%
-92.9%
▼ 85 pts
Net margin
-36.9%
-3.1%
-89.9%
▼ 87 pts
Return on assets (ROA)
—
-1.8%
-70.9%
▼ 69 pts
Return on equity (ROE)
—
—
-295.7%
—
Free cash flow margin
-22.5%
12.3%
29.0%
▲ 17 pts
Current ratio
—
2.34×
1.47×
▼ 37%
Quick ratio
—
2.30×
1.43×
▼ 38%
HNGE price history
Price history is added with the daily price update and will appear after the next one.